A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis

Area of Science:

• Geriatric medicine
• Oncology
• Clinical diagnostics

Background:

• Frailty screening aims to identify older cancer patients needing geriatric assessment (GA) and avoid unnecessary assessments for fit patients.
• The clinical utility of frailty screening hinges on the accuracy of screening tests, which requires verification.

Purpose of the Study:

• To evaluate the diagnostic accuracy of the G8 Geriatric Screening Tool (G8) and modified G8 scores in identifying unfit older cancer patients.
• To assess the clinical benefit of frailty screening versus a universal GA strategy using decision curve analysis.

Main Methods:

• Cross-sectional analysis of 1,648 outpatients (≥70 years) with cancer from the ELCAPA cohort study.
• Diagnostic accuracy (sensitivity, specificity) of G8 and modified G8 was determined against GA results.
• Decision curve analysis calculated the net benefit of screening for detecting unfit patients and avoiding unnecessary GA.

Main Results:

• The G8 and modified G8 showed high sensitivity (85-86%) but moderate specificity (59-60%) in identifying unfit patients.
• Decision curve analysis indicated no significant clinical benefit of frailty screening over a GA-for-all strategy.
• Screening tools did not reduce unnecessary GA in fit patients across various threshold probabilities.

Conclusions:

• Despite good diagnostic accuracy, frailty screening demonstrated no clear clinical advantage over universal geriatric assessment.
• Net benefit analysis, beyond diagnostic accuracy, is crucial for evaluating the clinical value of screening tools.
• The findings suggest current frailty screening protocols may not optimize resource allocation in geriatric oncology.